Health Care · Pharmaceutical Preparations

ABUS Arbutus Biopharma Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1447028112 filings
Russell 2000

ABUS at a glance

Arbutus Biopharma Corp (ABUS, SEC CIK 1447028) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Arbutus Biopharma Corp (ABUS) reported revenue of $14.1 million (up 128.2% from FY2024) and a net loss of $33.5 million. Diluted EPS was -$0.17.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Arbutus Biopharma Corp (ABUS) shares worth $288.1 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$14.1M
+128.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$288.1M · +2 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward risks include clinical development and regulatory approval uncertainty
  • Carried-forward risks include dependence on partnered product candidates and licensing arrangements
  • Carried-forward risks include liquidity needs and potential financing requirements

Management Discussion & Analysis

  • Q3 revenue $13.0M, down $0.2M YoY, reflecting lower ONPATTRO royalty revenue
  • Q3 operating loss $10.5M vs $8.7M loss YoY, operating margin -80.5% vs -67.2%
  • Best program: IM-PROVE II, 53% (33/62) achieved functional cure or remained off NA therapy
  • Cash and equivalents $264.2M at September 30, up from $18.0M; operating cash flow $225.7M
  • Capital deployment: $230M share repurchase settled October 5; AB-101 development resumed after FDA clinical hold lifted

AI summary of the ABUS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 8.01: Other Events

  • Updated corporate presentation posted November 12, 2026
  • Investor relevance depends on substantive pipeline, clinical, financing or strategic updates in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q4 2026 corporate presentation highlights imdusiran as the lead cHBV asset, with potential Phase 2b development plans under evaluation
  • Cash and equivalents of $104.6M as of October 31, 2026, supporting near-term clinical development
Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter financial results for period ended September 30, 2026 announced
  • Investor-relevant details, including revenue, expenses and cash position, contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Cash and marketable securities $337.5M at September 30, up from $91.5M, strengthening funding for clinical programs
  • $230M tender offer repurchased 46M shares at $5.00, approximately 23% of outstanding shares, materially reducing share count
Filed Oct 22, 2026Full analysis →

Item 8.01: Other Events

  • FDA clinical hold lifted for AB-101, Arbutus’s oral PD-L1 inhibitor
  • Clinical development can resume, reducing a key regulatory obstacle

Item EX-99.1: Item EX-99.1

  • FDA clinical hold lifted for AB-101, restoring U.S. clinical development eligibility
  • AB-101 Phase 1a/1b data showed generally good tolerability and high receptor occupancy in seven cHBV patients

AI summaries of ABUS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ABUS

Don't miss the next ABUS filing

  • Alerts as it files. A push when ABUS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ABUS, by share count.
  • Ask anything. An AI agent that reads every ABUS filing and answers with sources.

ABUS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Beardsley Robert ADOct 1, 2026$5.00
Roivant Sciences Ltd.DOct 1, 2026$5.00
Androski LindsayDOct 1, 2026$5.00
Nguyen TuanDOct 1, 2026$5.00
Sawhney RogerDOct 1, 2026$5.00
Androski LindsayMSep 18, 2026$3.20
Nguyen TuanMSep 18, 2026$4.39
Nguyen TuanMSep 18, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$6.2M$14.1M
Operating Income--$76.3M-$38.2M
Net Income-$72.8M-$69.9M-$33.5M
Op. Margin--1236.7%-271.0%
Net Margin--1133.0%-237.9%
Balance Sheet
Total Assets$144.4M$131.7M$94.6M
Equity-$97.4M$76.6M
ROE--71.8%-43.7%
Per Share
EPS$-0.44$-0.38$-0.17
Cash Flow
Operating CF--$64.8M-$39.6M
CapEx$1.0M$182K$0

Source: XBRL data in Arbutus Biopharma Corp (ABUS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ABUS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ABUS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$288.1M
Q2 202625$281.7M
Q1 202624$274.4M
Q4 202520$297.6M
Q3 202522$266.6M
Q2 202526$181.8M
Q1 202523$149.9M
Q4 202418$55.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ABUS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
8-KOct 22, 2026Analysis-
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 5, 2026--
4Sep 23, 2026--
4Sep 23, 2026--
4Sep 23, 2026--
4Sep 23, 2026--
SC 13GSep 4, 2026-
8-KAug 21, 2026Analysis-
10-QAug 12, 2026Analysis
8-KAug 12, 2026Analysis-
8-KJul 16, 2026Analysis-
4Jun 10, 2026-
4Jun 10, 2026-
8-KMay 27, 2026Analysis
8-KMay 13, 2026Analysis
10-QMay 13, 2026Analysis
8-KApr 15, 2026Analysis-
10-KMar 23, 2026-

Related Health Care companies

All Health Care →

ABUS SEC filings: frequently asked questions

Which institutions hold ABUS stock?

As of September 30, 2026, the largest Arbutus Biopharma Corp (ABUS) holders among the 13F filers tracked by SignalX were Morgan Stanley ($87.8 million), BlackRock ($69.4 million), State Street Corp ($33.9 million), Vanguard Capital Management LLC ($33.4 million), Millennium Management ($14.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ABUS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Arbutus Biopharma Corp (ABUS) reported revenue of $14.1 million (up 128.2% from FY2024) and a net loss of $33.5 million. Diluted EPS was -$0.17. The figures come from the XBRL data in the 10-K.

What did ABUS report in its latest 8-K?

Arbutus Biopharma Corp (ABUS) filed an 8-K on November 12, 2026 reporting Item 8.01 (Other Events). Updated corporate presentation posted November 12, 2026.

What are the latest ABUS SEC filings?

Arbutus Biopharma Corp (ABUS) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 7, 2026.

What is ABUS's SEC CIK number?

Arbutus Biopharma Corp (ABUS)'s SEC Central Index Key (CIK) is 1447028. EDGAR lists every ABUS filing under that number.

Ask anything about ABUS

The research agent reads ABUS's filings, financials, insider trades and 13F holders, then answers with sources.